Aptorum Group Limited announced the commercial launch of NativusWell, a new dietary supplement supporting women's health throughout the Menopausal cycles targeting the China market. NativusWell has commenced collaboration with one of the e-commerce platforms in China, JD.com, and NativusWell is now distributable in China via JD. China has the population in the world.

In 2010, there were over 130 million women aged 45 to 59 in China1. China accounts for about 11.4% of the market share in 2021 in the global menopause treatment market. The growing elderly population and the need for healthcare services present an opportunity for the menopause market to flourish.

NativusWell contains a novel, non-hormonal bioactive ingredient DOI, designed to support the overall health of women undergoing perimenopause, menopause and postmenopause. The product is now available on JD (also known as Jingdong), a leading e-commerce company in China. The presence of China's e-commerce market inaugurated a new era of the country's economy.

In 2020, the added value of the digital economy accounted for more than 38% of the country's GDP. In the same year, nearly a quarter of China's physical goods retail sales were sold online, far above the global average of 18%. In 2021, China contributed to more than half of the world's e-commerce retail sales, with the sales value surpass the combined total of Europe and the United States.

China has the digital buyer population in the world, amounting to more than 780 million people. By leveraging the large consumer base in JD, NativusWell targets to reach an extensive network of potential customers in China. Aptorum Group announced this collaboration with JD and is also actively expanding its targeted markets to include the US, EU and UK for further distribution of NativusWell and its future brand of potential products.